|
199 Companies |
|
329 Products |
|
329 Products |
|
164 Mechanisms of Action |
|
13 Trials |
|
3299 News |
|
| «12345678910111213...6768» |
- | melphalan / Generic mfg.
Trial completion, Trial initiation date, Trial primary completion date: Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation (clinicaltrials.gov) - Jul 21, 2017
P2, N=24, Completed, Sponsor: Medical College of Wisconsin
Active, not recruiting --> Completed | Initiation date: Jul 2016 --> Nov 2016 | Trial primary completion date: Oct 2025 --> Jun 2017
- | Ninlaro (ixazomib) / Takeda
Trial completion, Trial primary completion date: Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov) - Jul 19, 2017
P1, N=19, Completed, Sponsor: Millennium Pharmaceuticals, Inc.
Active, not recruiting --> Completed | Initiation date: Jul 2016 --> Nov 2016 | Trial primary completion date: Oct 2025 --> Jun 2017 Active, not recruiting --> Completed | Trial primary completion date: Jul 2019 --> Apr 2017
- | Trial completion, Enrollment change: Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer (clinicaltrials.gov) - Jul 19, 2017
P1, N=29, Completed, Sponsor: California Cancer Consortium
Active, not recruiting --> Completed | Trial primary completion date: Jul 2019 --> Apr 2017 Active, not recruiting --> Completed | N=40 --> 29
- | vinorelbine tartrate / Generic mfg., gemcitabine / Generic mfg.
Enrollment closed: Vinorelbine and Gemcitabine in Myeloma (clinicaltrials.gov) - Jul 18, 2017
P2, N=136, Active, not recruiting, Sponsor: University Hospital Inselspital, Berne
Active, not recruiting --> Completed | N=40 --> 29 Recruiting --> Active, not recruiting
- | leuprolide acetate for depot suspension / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Preservation of Ovarian Function After Hematopoietic Cell Transplant (clinicaltrials.gov) - Jul 17, 2017
P2, N=19, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Recruiting --> Active, not recruiting N=47 --> 19 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2014 --> Apr 2015
- | Rituxan (rituximab) / Roche
Trial completion: PLRG4: First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. (clinicaltrials.gov) - Jul 17, 2017
P3, N=250, Completed, Sponsor: Polish Lymphoma Research Group
N=47 --> 19 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2014 --> Apr 2015 Active, not recruiting --> Completed
- | cyclophosphamide / Generic mfg.
Enrollment closed, Trial primary completion date, Post-transplantation: Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide (clinicaltrials.gov) - Jul 13, 2017
P1/2, N=127, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Jun 2019
- ||| Ninlaro (ixazomib) / Takeda
Enrollment closed, Trial primary completion date, Combination therapy: Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma (clinicaltrials.gov) - Jul 12, 2017
P1/2, N=64, Active, not recruiting, Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Jun 2019 Completed --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Oct 2014
- |||| Darzalex IV (daratumumab) / J&J
Clinical: Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma (clinicaltrials.gov) - Jul 12, 2017
P2, N=104, Completed, Sponsor: Janssen Research & Development, LLC
Completed --> Active, not recruiting | Trial primary completion date: Apr 2015 --> Oct 2014 Active, not recruiting --> Completed
- NovoSeven (eptacog alfa) / Novo Nordisk
Trial completion, Enrollment change: A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan (clinicaltrials.gov) - Jul 11, 2017
P=N/A, N=4, Completed, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=10 --> 4
- | bortezomib / Generic mfg., lenalidomide / Generic mfg., sirolimus / Generic mfg.
Trial completion: EMN-alloRIC: Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation (clinicaltrials.gov) - Jul 6, 2017
P2, N=49, Completed, Sponsor: European Myeloma Network
Active, not recruiting --> Completed | N=10 --> 4 Recruiting --> Completed
- | pegylated liposomal doxorubicin / Generic mfg., thalidomide / Generic mfg.
Trial completion, HEOR: A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life (clinicaltrials.gov) - Jul 2, 2017
P2, N=25, Completed, Sponsor: University of Kansas Medical Center
Recruiting --> Completed Withdrawn --> Completed
- | Trial completion: Study of Megakaryocytes From Patients With Abnormal Platelet Vesicles (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=3, Completed, Sponsor: National Human Genome Research Institute (NHGRI)
Withdrawn --> Completed Recruiting --> Completed
- | Trial completion: Study of Abnormal Blood Clotting in Children With Stroke (clinicaltrials.gov) - Jun 30, 2017
P=N/A, N=130, Completed, Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting --> Completed Recruiting --> Completed
- | alvocidib (DSP-2033) / Sumitomo Pharma
Trial completion: Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma (clinicaltrials.gov) - Jun 30, 2017
P1/2, N=52, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Completed
- | cyclophosphamide / Generic mfg.
Trial completion: Treatment of Autoimmune Thrombocytopenia (AITP) (clinicaltrials.gov) - Jun 30, 2017
P1, N=29, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting --> Completed Recruiting --> Completed
- letetresgene autoleucel (GSK3377794) / Adaptimmune
Trial primary completion date: CT Antigen TCR-Engineered T Cells for Myeloma (clinicaltrials.gov) - Jun 29, 2017
P1/2, N=10, Active, not recruiting, Sponsor: Adaptimmune
Recruiting --> Completed Trial primary completion date: Apr 2017 --> Dec 2017
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, plerixafor / Generic mfg.
Enrollment change: Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Jun 28, 2017
P=N/A, N=1, Terminated, Sponsor: Fred Hutchinson Cancer Research Center
Trial primary completion date: Apr 2017 --> Dec 2017 N=20 --> 1
- | melphalan / Generic mfg.
Phase classification: Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients (clinicaltrials.gov) - Jun 27, 2017
P=N/A, N=148, Completed, Sponsor: Ohio State University Comprehensive Cancer Center
N=20 --> 1 Phase classification: P2 --> P=N/A
- | Trial completion: Collection of Patient-Reported Symptoms and Performance Status Via the Internet (clinicaltrials.gov) - Jun 27, 2017
P=N/A, N=325, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Phase classification: P2 --> P=N/A Active, not recruiting --> Completed
- | clarithromycin / Generic mfg., thalidomide / Generic mfg.
Trial completion: Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant (clinicaltrials.gov) - Jun 26, 2017
P2, N=30, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Cablivi (caplacizumab) / Sanofi
Enrollment closed: HERCULES: Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura (clinicaltrials.gov) - Jun 23, 2017
P3, N=145, Active, not recruiting, Sponsor: Ablynx
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Jivi (damoctocog alfa pegol) / Bayer
Trial primary completion date, Interview: Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A (clinicaltrials.gov) - Jun 22, 2017
P=N/A, N=30, Not yet recruiting, Sponsor: Bayer
Recruiting --> Active, not recruiting Trial primary completion date: Jun 2017 --> Oct 2017
- || Zontivity (vorapaxar) / Merck (MSD)
Trial primary completion date: ADVICE: Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints (clinicaltrials.gov) - Jun 22, 2017
P1/2, N=60, Recruiting, Sponsor: Kirby Institute
Trial primary completion date: Jun 2017 --> Oct 2017 Trial primary completion date: Sep 2017 --> Dec 2017
- | deferasirox tablet for oral suspension / Generic mfg.
Phase classification: Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies (clinicaltrials.gov) - Jun 20, 2017
P2, N=16, Completed, Sponsor: Wake Forest University Health Sciences
Trial primary completion date: Sep 2017 --> Dec 2017 Phase classification: P=N/A --> P2
- | aspirin / Generic mfg.
Trial primary completion date: High-Shear Microfluidic Thrombosis Assay (clinicaltrials.gov) - Jun 19, 2017
P=N/A, N=45, Enrolling by invitation, Sponsor: Emory University
Phase classification: P=N/A --> P2 Trial primary completion date: May 2017 --> May 2018
- | Trial primary completion date: FOX-TREG: Study of the Role of Regulator T Cells in the Pathophysiology of Childhood Henoch Schönlein Purpura (clinicaltrials.gov) - Jun 19, 2017
P=N/A, N=120, Recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
Trial primary completion date: May 2017 --> May 2018 Trial primary completion date: Feb 2017 --> Feb 2018
- CB-5083 / Cleave Therap
Trial termination: A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies (clinicaltrials.gov) - Jun 19, 2017
P1, N=120, Terminated, Sponsor: Cleave Biosciences, Inc.
Trial primary completion date: Feb 2017 --> Feb 2018 Recruiting --> Terminated; MTD determined
- |||| carfilzomib / Generic mfg.
Clinical: A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols (clinicaltrials.gov) - Jun 19, 2017
P2, N=100, Completed, Sponsor: Amgen
Recruiting --> Terminated; MTD determined Active, not recruiting --> Completed
- colesevelam / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCT (clinicaltrials.gov) - Jun 14, 2017
P2, N=4, Terminated, Sponsor: Mayo Clinic
Active, not recruiting --> Completed N=48 --> 4 | Recruiting --> Terminated | Trial primary completion date: Jan 2018 --> Dec 2016; Difficulty recruiting; pill burden and nausea were barriers
- | melphalan / Generic mfg.
Enrollment closed: Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation (clinicaltrials.gov) - Jun 14, 2017
P2, N=24, Active, not recruiting, Sponsor: Medical College of Wisconsin
N=48 --> 4 | Recruiting --> Terminated | Trial primary completion date: Jan 2018 --> Dec 2016; Difficulty recruiting; pill burden and nausea were barriers Recruiting --> Active, not recruiting
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment change, Metastases: Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies (clinicaltrials.gov) - Jun 14, 2017
P=N/A, N=100, Completed, Sponsor: University of Illinois at Chicago
Recruiting --> Active, not recruiting N=152 --> 100
- | Trial primary completion date: TEG (Thromboelastography) Based Versus Conventional Coagulation Parameters Based Correction of Coagulopathy in Non Variceal Bleed. (clinicaltrials.gov) - Jun 9, 2017
P=N/A, N=130, Recruiting, Sponsor: Institute of Liver and Biliary Sciences, India
N=152 --> 100 Trial primary completion date: Feb 2017 --> Dec 2017
- | Amevive (alefacept) / Astellas
Trial termination: Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Jun 7, 2017
P=N/A, N=3, Terminated, Sponsor: Emory University
Trial primary completion date: Feb 2017 --> Dec 2017 Suspended --> Terminated; drug company is no longer making the drug
- | lenalidomide / Generic mfg.
Trial completion: Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia (clinicaltrials.gov) - Jun 7, 2017
P1/2, N=17, Completed, Sponsor: University Hospital, Lille
Suspended --> Terminated; drug company is no longer making the drug Active, not recruiting --> Completed
- Venclexta (venetoclax) / Roche, AbbVie, azintuxizumab vedotin (ABBV-838) / AbbVie
Enrollment change, Trial initiation date, Trial withdrawal, Combination therapy: A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment (clinicaltrials.gov) - Jun 5, 2017
P1b, N=0, Withdrawn, Sponsor: AbbVie
Active, not recruiting --> Completed N=72 --> 0 | Initiation date: May 2017 --> Aug 2017 | Recruiting --> Withdrawn
- azintuxizumab vedotin (ABBV-838) / AbbVie
Clinical: Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 4, 2017
P1, N=74, Terminated, Sponsor: AbbVie
N=72 --> 0 | Initiation date: May 2017 --> Aug 2017 | Recruiting --> Withdrawn N=161 --> 74 | Active, not recruiting --> Terminated; No Go decision for ABBV-838
- | Trial completion, Combination therapy: Combination Study of Revlimid (clinicaltrials.gov) - Jun 2, 2017
P1/2, N=74, Completed, Sponsor: University of Michigan Cancer Center
N=161 --> 74 | Active, not recruiting --> Terminated; No Go decision for ABBV-838 Active, not recruiting --> Completed
- | VLX1570 / Vivolux
Trial suspension, Trial primary completion date: A Study of VLX1570 and Dexamethasone in Myeloma Patients (clinicaltrials.gov) - Jun 2, 2017
P1/2, N=70, Suspended, Sponsor: Vivolux AB
Active, not recruiting --> Completed Recruiting --> Suspended | Trial primary completion date: Jan 2017 --> Dec 2017
- || Empliciti (elotuzumab) / AbbVie, BMS, lirilumab (BMS-986015) / Innate, BMS, Ono Pharma, urelumab (BMS-663513) / BMS, Ono Pharma
Trial primary completion date, Combination therapy: A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma (clinicaltrials.gov) - Jun 1, 2017
P1, N=136, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Recruiting --> Suspended | Trial primary completion date: Jan 2017 --> Dec 2017 Trial primary completion date: Apr 2017 --> Feb 2018
- Enrollment change, Trial termination: Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects (clinicaltrials.gov) - May 31, 2017
P=N/A, N=44, Terminated, Sponsor: University of Arkansas
Trial primary completion date: Apr 2017 --> Feb 2018 N=100 --> 44 | Active, not recruiting --> Terminated; PI does not have time to continue study
- NovoEight (turoctocog alfa) / Novo Nordisk
Enrollment closed: guardian ™9: Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A (clinicaltrials.gov) - May 31, 2017
P1, N=35, Active, not recruiting, Sponsor: Novo Nordisk A/S
N=100 --> 44 | Active, not recruiting --> Terminated; PI does not have time to continue study Recruiting --> Active, not recruiting
- | fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial completion, Trial initiation date, Trial primary completion date: Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease (clinicaltrials.gov) - May 30, 2017
P2, N=71, Completed, Sponsor: UNC Lineberger Comprehensive Cancer Center
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Initiation date: Nov 2003 --> Jan 2011 | Trial primary completion date: Dec 2016 --> Jan 2011
- | Enrollment change, Trial initiation date, Trial primary completion date: CARROM: Efficacy and Safety of Heparin-grafted Membrane for CRRT (clinicaltrials.gov) - May 30, 2017
P=N/A, N=20, Completed, Sponsor: National University Hospital, Singapore
Active, not recruiting --> Completed | Initiation date: Nov 2003 --> Jan 2011 | Trial primary completion date: Dec 2016 --> Jan 2011 N=30 --> 20 | Initiation date: Mar 2013 --> Aug 2013 | Trial primary completion date: Feb 2015 --> Dec 2016
- | Trial completion, Enrollment change: National Survey of People With Haemophilia in Portugal (clinicaltrials.gov) - May 24, 2017
P=N/A, N=146, Completed, Sponsor: University of Minho
N=30 --> 20 | Initiation date: Mar 2013 --> Aug 2013 | Trial primary completion date: Feb 2015 --> Dec 2016 Enrolling by invitation --> Completed | N=477 --> 146
- | Enrollment open, Trial initiation date, Trial primary completion date: MELODY: To Compare Conservative Management Vs. Balloon Kyphoplasty in the Treatment of VCFs in Patients With Multiple Myeloma (clinicaltrials.gov) - May 23, 2017
P=N/A, N=156, Recruiting, Sponsor: Royal National Orthopaedic Hospital NHS Trust
Enrolling by invitation --> Completed | N=477 --> 146 Active, not recruiting --> Recruiting | Initiation date: Oct 2015 --> May 2017 | Trial primary completion date: Oct 2016 --> May 2019
- busulfan / Generic mfg.
Phase classification: Busulfan in Multiple Myeloma (clinicaltrials.gov) - May 23, 2017
P1, N=13, Terminated, Sponsor: Guido Tricot
Active, not recruiting --> Recruiting | Initiation date: Oct 2015 --> May 2017 | Trial primary completion date: Oct 2016 --> May 2019 Phase classification: P1/2 --> P1
- | Trial completion: Study of DNA Samples From Patients With Multiple Myeloma (clinicaltrials.gov) - May 19, 2017
P=N/A, N=600, Completed, Sponsor: ECOG-ACRIN Cancer Research Group
Phase classification: P1/2 --> P1 Not yet recruiting --> Completed
- | lenalidomide / Generic mfg., thalidomide / Generic mfg.
Trial completion: Studying Blood Samples From Patients With Multiple Myeloma Who Were Treated With Thalidomide or Lenalidomide (clinicaltrials.gov) - May 17, 2017
P=N/A, N=33, Completed, Sponsor: Eastern Cooperative Oncology Group
Not yet recruiting --> Completed Not yet recruiting --> Completed
- | Trial initiation date, Metastases: CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice (clinicaltrials.gov) - May 16, 2017
P=N/A, N=150000, Not yet recruiting, Sponsor: Molecular Evidence Development Consortium Inc.
Not yet recruiting --> Completed Initiation date: Oct 2016 --> May 2017